M. Roelvink

发表

Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.

E. D. de Vries, J. Wanders, P. Fumoleau, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.

D. Dunlop, J. Smyth, T. Cerny, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours

S. Aamdal, J. Wanders, J. Vermorken, 2001, Cancer Chemotherapy and Pharmacology.

First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers

A. Tutt, J. Carmichael, J. Schellens, 2007 .

Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies

M. Gore, R. Paridaens, J. Wanders, 2002, Investigational New Drugs.

AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

J. Carmichael, J. Bono, J. Schellens, 2008 .

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

G. Giaccone, C. Punt, J. Beijnen, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.

R. Paridaens, J. Wanders, J. Verweij, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Taxotere toxicity — Protective effects of premedication

M. Piccart, M. Gore, J. Wanders, 1993 .

Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG).

J. Wanders, C. Sessa, P. Dombernowsky, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.

M. Borner, J. Smyth, P. Fumoleau, 2001, European journal of cancer.

A phase I study of E7080 in patients (pts) with advanced malignancies

J. Wanders, J. Schellens, A. Mazur, 2008 .

A Phase I study of men-10755 in patients with a solid tumor as a shorti.v. infusion given once every 3 weeks

S. Aamdal, S. Peters, J. Wanders, 1999 .

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

J. Schellens, E. Voest, H. Verheul, 2008 .